First-line ICIs in renal cell carcinoma

Treatment of metastatic renal cell carcinoma (mRCC) has radically changed, switching from interferon alfa (IFN-α) and high-dose interleukin−2 (HD IL−2) to new targeted therapies directed against tumoral neoangiogenesis, the mammalian target of the rapamycin (mTOR) pathway and immune checkpoints. Of...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiorentino, Vincenzo, Tralongo, Pietro, Larocca, Luigi Maria, Pizzimenti, Cristina, Martini, Maurizio, Pierconti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Immunotherapy - Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332208/
https://www.ncbi.nlm.nih.gov/pubmed/37395601
http://dx.doi.org/10.1080/21645515.2023.2225386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332208/
https://www.ncbi.nlm.nih.gov/pubmed/37395601
http://dx.doi.org/10.1080/21645515.2023.2225386

Ejemplares similares